Answers are grounded in this paper and cite their sources.
The pharmacokinetics of abatacept and the association between abatacept exposure and outcomes in patients with severe COVID-19 are unknown.
No takes yet. Share an insight, caveat, or question.
Balevic et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: